Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily LIXIANA® (edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session

DAIICHI SANKYO EUROPE GmbH: Munich (ots/PRNewswire) – – Four abstracts highlight new subgroup analyses from the global phase 3 ENGAGE AF-TIMI 48 and Hokusai-VTE studies to be presented in oral and poster sessions Daiichi Sankyo Europe GmbH Group (hereafter, Daiichi …

Das könnte Sie interessieren

Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance in Europe
German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation